Monkeypox Outbreak - Nine States, May 2022.

On May 17, 2022, the Massachusetts Department of Public Health (MDPH) Laboratory Response Network (LRN) laboratory confirmed the presence of orthopoxvirus DNA via real-time polymerase chain reaction (PCR) from lesion swabs obtained from a Massachusetts resident. Orthopoxviruses include Monkeypox virus, the causative agent of monkeypox. Subsequent real-time PCR testing at CDC on May 18 confirmed that the patient was infected with the West African clade of Monkeypox virus. Since then, confirmed cases* have been reported by nine states. In addition, 28 countries and territories,† none of which has endemic monkeypox, have reported laboratory-confirmed cases. On May 17, CDC, in coordination with state and local jurisdictions, initiated an emergency response to identify, monitor, and investigate additional monkeypox cases in the United States. This response has included releasing a Health Alert Network (HAN) Health Advisory, developing interim public health and clinical recommendations, releasing guidance for LRN testing, hosting clinician and public health partner outreach calls, disseminating health communication messages to the public, developing protocols for use and release of medical countermeasures, and facilitating delivery of vaccine postexposure prophylaxis (PEP) and antivirals that have been stockpiled by the U.S. government for preparedness and response purposes. On May 19, a call center was established to provide guidance to states for the evaluation of possible cases of monkeypox, including recommendations for clinical diagnosis and orthopoxvirus testing. The call center also gathers information about possible cases to identify interjurisdictional linkages. As of May 31, this investigation has identified 17§ cases in the United States; most cases (16) were diagnosed in persons who identify as gay, bisexual, or men who have sex with men (MSM). Ongoing investigation suggests person-to-person community transmission, and CDC urges health departments, clinicians, and the public to remain vigilant, institute appropriate infection prevention and control measures, and notify public health authorities of suspected cases to reduce disease spread. Public health authorities are identifying cases and conducting investigations to determine possible sources and prevent further spread. This activity was reviewed by CDC and conducted consistent with applicable federal law and CDC policy.¶.

Rhabdomyolysis in patients with west nile encephalitis and meningitis.

Since 1999, more than 6,500 cases of West Nile virus neuroinvasive disease (WNND) have been reported in the United States. Patients with WNND can present with muscle weakness that is often assumed to be of neurological origin. During 2002, nearly 3,000 persons with WNV meningitis or encephalitis (or both) were reported in the United States; in suburban Cook County, Illinois, with 244 persons were hospitalized for WNV illnesses. The objective of this investigation was to describe the clinical and epidemiological features of identified cases of WNV neuroinvasive disease and rhabdomyolysis. Public health officials investigated patients hospitalized in Cook County, and identified a subset of WNV neuroinvasive disease patients with elevated creatine kinase levels. Cases were defined as hospitalized persons with a WNV infection, encephalitis or meningitis, and rhabdomyolysis. Retrospective medical record reviews were conducted and data was abstracted with a standardized data collection instrument. Eight patients with West Nile encephalitis and one with West Nile meningitis were identified with rhabdomyolysis. Median age of the nine patients was 70 years (range, 45-85 years), and eight were men. For all nine patients, the peak CK level was documented a median of 2 days after hospitalization (range, 1-24 days). Median CK level during hospitalization for all case-patients was 3,037 IU (range, 1,153-42,113 IU). Six patients had history of recent falls prior to admission. Although the temporal relationship of rhabdomyolysis and neurological WNV illness suggested a common etiology, these patients presented with complex clinical conditions which may have led to development of rhabdomyolysis from other causes. The spectrum of WNV disease requires further investigation to describe this and other clinical conditions associated with WNV infection.

Serologic survey of cats and dogs during an epidemic of West Nile virus infection in humans.

OBJECTIVE: To estimate West Nile virus (WNV) infection rates, assess environmental variables that correlated with seropositivity in dogs and cats, and assess whether pets should be considered as possible sentinels for WNV and therefore of potential human exposure. DESIGN: Cross-sectional serosurvey. ANIMALS: 442 dogs and 138 cats. PROCEDURE: Serum samples were screened for seropositivity against WNV by use of the plaque reduction neutralization test. RESULTS: 116 (26%) dogs and 13 (9%) cats yielded positive results. The odds of seropositivity against WNV for outdoor-only family dogs were almost 19 times as great as those for indoor-only family dogs and almost twice as great for stray dogs as for family dogs. Family dogs not receiving heartworm medication were 2.5 times as likely to yield positive results for antibodies against WNV as family dogs receiving heartworm medication. CONCLUSIONS AND CLINICAL RELEVANCE: Seropositivity was greater for outdoor family dogs than for indoor family dogs. Further investigation of the potential use of stray dogs as sentinel indicators for WNV infection and the potential risk of human exposure is warranted.

Lyme disease trends--Dutchess County, New York, 1992-2000.

BACKGROUND: Lyme disease is a vector-borne infectious disease, accounting for more than 95% of all reported vector-borne illness in the United States. From 1992 2000, Dutchess County reported more cases of Lyme disease than any other county in the United States, consistently ranking among the top ten in incidence rates. We analyzed 1992-2000 Dutchess County Lyme disease surveillance data to characterize Lyme disease trends, identify high-risk populations, and examine the frequency of the characteristic lesion, erythema migrans. METHODS: A Lyme disease case was defined as a person with physician-diagnosed erythema migrans or at least one late manifestation of the disease, with laboratory confirmation. A surveillance database of cases reported in Dutchess County from 1992-2000 was obtained from the New York State Department of Health. Annual incidence rates by age, gender, race, ethnicity, and ZIP codes, and frequency of erythema migrans were calculated. RESULTS: From 1992 through 2000, a total of 9,548 cases of Lyme disease were reported by Dutchess County to the New York State Department of Health, for a crude mean annual incidence rate of 400 cases per 100,000 persons per year. The incidence rate peaked at 683/100,000 in 1996, and then declined from 1998 to 2000. A bimodal age distribution was seen, with the initial peak among children aged 5-9 years (617/100,000) and the second peak among adults aged 60-64 years (627/100,000). A male preponderance was clearly seen between the ages of 5-19 years, and beyond the age of 60 years. Highest incidence rates were reported in central Dutchess County. Onset of illness occurred most frequently in June, July, and August. Ninety-four percent of cases occurred among the predominantly white population, which had the highest incidence rate (431/100,000) among the races. Incidence rate for non-Hispanics was more than double that for Hispanics. Eighty-one percent of reported cases had erythema migrans. CONCLUSIONS: While some prevention programs could be broadly targeted to the entire Dutchess County population, other interventions might be most effective if they focused on the high-risk population groups and areas defined in this report. The high proportion of cases with erythema migrans suggests that early diagnosis and treatment should be effective in reducing late-stage complications of Lyme disease in Dutchess County. Surveillance data for other endemic counties and states can be similarly analyzed to enhance and monitor local prevention programs.

What we are watching--five top global infectious disease threats, 2012: a perspective from CDC's Global Disease Detection Operations Center.

Disease outbreaks of international public health importance continue to occur regularly; detecting and tracking significant new public health threats in countries that cannot or might not report such events to the global health community is a challenge. The Centers for Disease Control and Prevention's (CDC) Global Disease Detection (GDD) Operations Center, established in early 2007, monitors infectious and non-infectious public health events to identify new or unexplained global public health threats and better position CDC to respond, if public health assistance is requested or required. At any one time, the GDD Operations Center actively monitors approximately 30-40 such public health threats; here we provide our perspective on five of the top global infectious disease threats that we were watching in 2012: 1 avian influenza A (H5N1), 2 cholera, 3 wild poliovirus, 4 enterovirus-71, and 5 extensively drug-resistant tuberculosis11†Current address: Division of Integrated Biosurveillance, Armed Forces Health Surveillance Center, US Department of Defense, Silver Spring, MD, USA.